Leqembi Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of alzheimer’s disease, advancements in monoclonal antibody research, growing awareness of early diagnosis importance, expansion of neurology specialty care, regulatory approvals for targeted therapies.

The growth in the forecast period can be attributed to increasing investments in neurodegenerative disease research, rising adoption of early diagnostic tools, expansion of personalized alzheimer’s treatment protocols, growing focus on slowing disease progression, increased payer coverage for innovative therapies. Major trends in the forecast period include increasing adoption of amyloid-targeting therapies, rising focus on early-stage alzheimer’s intervention, growing demand for disease-modifying neurodegenerative treatments, expansion of biomarker-guided patient selection, enhanced monitoring of cognitive outcomes.

The growing prevalence of Alzheimer’s disease is expected to drive the growth of the Leqembi market in the future. Alzheimer’s disease is a degenerative brain disorder that progressively affects memory, cognition, and behavior, ultimately disrupting daily life. It is a complex condition influenced by a combination of genetic, lifestyle, and environmental factors. Leqembi works by reducing beta-amyloid plaques in the brain, which helps slow cognitive decline in the early stages of Alzheimer’s by targeting these plaques and protecting memory and cognitive functions. For example, in September 2024, the European Brain Council, a Belgium-based international health organization, reported that approximately 7 million people in Europe are currently living with Alzheimer’s disease, and this number is expected to double to 14 million by 2030 due to an aging population. This makes Alzheimer’s disease a significant global public health challenge. As a result, the increasing prevalence of Alzheimer’s disease is fueling the growth of the Leqembi market.

One of the key strategies in the Leqembi market is the development of advanced intravenous (IV) maintenance dosing formulations aimed at reducing the frequency of administration for individuals with Alzheimer’s disease. An intravenous maintenance dosing formulation involves administering a consistent or recurring dose of medication directly into the bloodstream to sustain therapeutic levels over a prolonged period. For example, in June 2024, Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) had accepted a supplemental biologics license application (sBLA) for a monthly LEQEMBI intravenous maintenance dosing regimen. This treatment specifically targets toxic amyloid proteins, particularly protofibrils, which are believed to contribute to cognitive decline in Alzheimer's disease. LEQEMBI has demonstrated clinical and biomarker benefits, including extended treatment efficacy, a potential reduction in neuronal damage, and the improvement of long-term patient outcomes.

In November 2024, Biogen Inc., a US-based biotechnology company, formed a partnership with Eisai Co., Ltd. The collaboration focuses on the development and commercialization of treatments for Alzheimer’s disease, with particular emphasis on Leqembi (lecanemab) for patients in the early stages of the disease. Eisai Co., Ltd., a Japan-based pharmaceutical company, manufactures Leqembi.

Major companies operating in the leqembi market are Eisai Co. Ltd.

North America was the largest region in the leqembi market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqembi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the leqembi market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the leqembi market by increasing costs related to imported biologic manufacturing components, diagnostic imaging reagents, infusion equipment, and cold-chain distribution systems. North America and Europe are most affected due to reliance on international biologics supply networks and advanced diagnostic infrastructure, while Asia-Pacific faces elevated import costs for branded neurotherapies. These tariffs raise treatment and diagnostic expenses and affect reimbursement dynamics. However, they are also driving domestic biologics manufacturing investments, regional clinical infrastructure development, and localized production of neurodegenerative therapeutics.

The leqembi market research report is one of a series of new reports that provides leqembi market statistics, including leqembi industry global market size, regional shares, competitors with a leqembi market share, detailed leqembi market segments, market trends and opportunities, and any further data you may need to thrive in the leqembi industry. This leqembi market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Leqembi (generic name: lecanemab) is a prescription medication used to treat Alzheimer’s disease, a progressive neurodegenerative disorder that causes memory loss, cognitive decline, and impaired daily functioning. The drug specifically targets the underlying pathology of Alzheimer’s by reducing amyloid-beta plaques in the brain, which are believed to contribute to the disease's progression.

The primary formulations of Leqembi include injectable formulations (intravenous) and ready-to-use solutions. The intravenous injectable formulation delivers the medication directly into the bloodstream for rapid absorption and precise dosing. This is typically used for patients with advanced conditions or those who require consistent medication levels. Leqembi is used for various indications, including the treatment of Alzheimer’s disease, management of mild cognitive impairment, and other conditions across different patient demographics, such as adult and geriatric patients, as well as individuals with early-stage Alzheimer’s disease. It is distributed through multiple channels, including direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies. Key end users include hospitals, neurology clinics, memory care facilities, and home healthcare providers.

The leqembi market consists of sales of oral tablets or capsules, subcutaneous injections, and transdermal patches. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.